Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors
NCT00086528
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
41
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
Interventions
DRUG:
XL647
Sponsor
Kadmon Corporation, LLC